M
Masakazu Toi
Researcher at Kyoto University
Publications - 658
Citations - 28522
Masakazu Toi is an academic researcher from Kyoto University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 69, co-authored 578 publications receiving 23200 citations. Previous affiliations of Masakazu Toi include The Breast Cancer Research Foundation & Tokyo Metropolitan Komagome Hospital.
Papers
More filters
Proceedings ArticleDOI
Abstract P1-06-05: DNA methylation-based classification are mostly concordant with intrinsic subtypes of breast cancer
TL;DR: High-resolution methylation analysis revealed methylation-based clusters were concordant with intrinsic subtypes in BC cells, and whether specific DNA methylation patterns exist in CGIs, shores and shelves inBC cells was determined.
Proceedings ArticleDOI
Abstract 2357: Knockdown of neuropilin-1 in monocytes impaired lymphocyte migration and anti-tumor activity in a humanized mouse model
Kosuke Kawaguchi,Eiji Suzuki,Isao Kii,Tatsuki R. Kataoka,Masahiro Hirata,Hironori Haga,Masatoshi Hagiwara,Masakazu Toi +7 more
TL;DR: The data suggest that NRP-1-expressing immune cells initiate anti-tumor activity via migration and chemokine secretion in HER2-positive breast cancer patients, using a tumor-bearing NOD/Shi-SCID, IL-2Rγnull(NOG) mouse model.
Journal Article
Controversies in endocrine therapy for breast cancer
TL;DR: Differences between Als and tamoxifen as well as non-steroidal and steroidal Als in their long-term adverse effects on bone demineralization and lipid metabolism are only starting to emerge and may lead to a more reliable endocrine therapy modality in the treatment of breast cancer.
Journal Article
Primary systemic chemotherapy for breast cancer
Masahiro Takada,Masakazu Toi +1 more
TL;DR: There has been an increasing demand to provide a tailored treatment in neoadjuvant chemotherapy with establishment of genetic testing for biological markers and adjustment of therapeutic strategy following identification of the early treatment response.
Journal ArticleDOI
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Nicholas C. Turner,Mafalda Melo Oliveira,Sacha J Howell,Florence Dalenc,Javier Cortes,Henry L. Gomez Moreno,Xichun Hu,Komal Jhaveri,Petr Krivorotko,Sibylle Loibl,S. Morales Murillo,Meena Okera,Yeon Hee Park,Joohyuk Sohn,Masakazu Toi,Eriko Tokunaga,Sami Yousef,L G Zhukova,Elza C de Bruin,Lynda Grinsted,Gaia Schiavon,Andrew Foxley,Hope S. Rugo +22 more
TL;DR: Capivasertib-fulvestrant therapy resulted in significantly longer progression-free survival than treatment with fulvestrant alone among patients with hormone receptor-positive advanced breast cancer whose disease had progressed during or after previous aromatase inhibitor therapy with or without a CDK4/6 inhibitor.